174900 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The firm was established to develop bio-synergy antibody therapeutics for overcoming intractable cancer. It offers antibodies and detection kits. The company was founded by Carl Erik Mathias Uhlén and Jong-Seo Lee on June 25, 2010 and is headquartered in Seoul, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
174900 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company